The analysis of pharmacotherapy for benign prostatic hyperplastic in outpatients in geriatrics department of three hospitals in Changsha
10.3760/cma.j.issn.0254-9026.2009.07.025
- VernacularTitle:长沙市三家医院老年病科门诊良性前列腺增生患者药物治疗情况分析
- Author:
Ying LIU
;
Xiaobing QU
;
Xiumei XIE
;
Shundong LI
;
Lini DONG
;
Zhigao HU
- Publication Type:Journal Article
- Keywords:
Prostatic hyperplasia;
Drug therapy
- From:
Chinese Journal of Geriatrics
2009;28(7):605-607
- CountryChina
- Language:Chinese
-
Abstract:
Objective To understand the elementary information and pharmacotherapy for benign prostatic hyperplasia (BPH) in outpatients in geriatrics department of three hospitals. Methods The outpatients diagnosed as BPH were investigated by daily BPH diagnosis report form, BPH medical-care requirement questionnaire, international prostate symptom score (IPSS) questionnaire and BPH quality of life scale (BPHQLS) in odd months. Results There were 657 outpatients in the three hospitals, including 456 males and 201 females. 289 patients were diagnosed as BPH, accounting for 44% of all outpatients and 63.4% of male patients. The average age of BPH patients was (77.2±5.7)years, the mean volume of prostate was (41.44 ± 21.00)ml, the median value of prostate specific antigen (PSA) was 2.24 μg/L, the mean maximum flow rate was (12. 65± 5.74)ml/s, and the average of IPSS and BPHQLS were 14.8±8. 11, 2. 56±1.36, respectively. The percentage of pharmacotherapy was 66.21% (96/145), and the rates of a-receptor blocker monotherapy and 5α-reduetase inhibitor monotherapy were 6.90% and 8. 97%, respectively. The percentage of drug combination was 26.90%. Conclusions BPH outpatients in geriatrics department of the three hospitals are at high risk, and most of them receive drug therapy. The drug choice is reasonable.
